"Patients with HNSCC cancer were given three doses of neoadjuvant anti-OX40 (MEDI6469) at 0.4 mg/kg, followed by surgery at days 8, 12, or 19. T-cell proliferation (Ki67) &amp; activation (ICOS) in peripheral blood following anti-OX40 administration peaks between D12 and D19."